Findings Suggest Persistent Treatment-Resistant AIDS Traces Due to Defective, Noninfectious Virus Copies

The findings should provide relief to many people living with HIV who fear viral rebound or infecting other people.

June 9, 2026

Key Highlights

Most residual HIV detected in treated patients originates from defective, noninfectious virus copies.
Mutations or deletions in the 5'-leader region of HIV-1 RNA are primary causes of persistent viral traces.
Clinicians can now analyze blood plasma to determine if detectable virus is infectious, improving treatment decisions.
This research offers reassurance to people living with HIV about the low risk of transmission despite detectable viral fragments.
The findings could lead to simplified treatment protocols, reducing medication burden and side effects.

New findings published in Science Communications suggest that most cases where AIDS patients retain traces of the virus despite taking antiretroviral drugs are explained by “defective and noninfectious copies of the virus.”

The study found that “while traces of HIV-1 RNA can persist in blood after optimal therapy, cases of non-suppressible viremia are driven by HIV-1 RNA with defects in a piece of the RNA known as 5’-leader.” These new findings should “provide relief to many people living with HIV who fear a viral rebound or who are concerned about transmitting the virus to partners despite taking effective treatment.”

The investigators studied blood samples from 52 people living with HIV who had detectable traces of the virus despite being on long-term therapies. Most detectable forms of the virus were “due to defective copies, and most defects were due to mutations or deletions in the 5’-leader region of HIV-1 RNA.”

The new study offers evidence that “clinicians can now study the virus in blood plasma and confirm if clinically detectable levels are due to defective copies released from one or a few T-cell clones, says Simonetti. If so, he adds, this could eliminate the need for extra medications and could prevent related complications.”